Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being...

from PR Newswire: https://ift.tt/3gVUdca